TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03303521

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .~Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Zirconium Cyclosilicate (ZS)
Description: Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .~Single dose contains from 1 to 3 sachets of ZS 5g depending on dose level assigned to a patient per non-dialysis days.
Study: NCT02130466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dabrafenib
Description: oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: oral tablet
Study: NCT02728947

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ROTIGOTINE
Description: 1 week at each dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ROTIGOTINE
Description: 1 week at each dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ROTIGOTINE
Description: 1 week at each dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ROTIGOTINE
Description: 1 week at each dose
Study: NCT00991471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interaction with MDRN STAT
Description: Interaction with MDRNSTAT at triage to obtain orders for investigations and/or treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No MDRNSTAT
Description: Standard management of nurse-only triage for assignment of CTAS
Study: NCT02228733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074
Description: Comparisons of different doses of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074
Description: Comparisons of different doses of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074
Description: Comparisons of different doses of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074
Description: Comparisons of different doses of study drug
Study: NCT02130466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: oral tablet
Study: NCT04365595

Intervention type: OTHER
Intervention: Questionnaires, spirometry
Description: Questionnaires targeting health-related quality-of-life, symptoms, anxiety and depression
Study: NCT00724152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: A psychotherapeutic approach to tinnitus management which includes tinnitus education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tinnitus Education
Description: An audiologic rehabilitative approach to tinnitus education.
Study: NCT02184754

Intervention type: PROCEDURE
Intervention: Magnetic endoscope imaging (MEI)
Study: NCT02159599

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir/Ritonavir
Description: Darunavir/ritonavir (800/100 mg): QD (quaque die )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Ritonavir
Description: Darunavir/ritonavir (800/100 mg): QD (quaque die )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Lamivudine (300mg) : QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine/tenofovir or abacavir/lamivudine
Description: Emtricitabine/tenofovir (300/200 mg) or abacavir/lamivudine (600/300 mg): QD
Study: NCT04137848

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT)
Description: OMT: 4-week manual therapeutic program with a weekly session of osteopathic examination and manipulation of somatic disfunctions in ambulatory setting. MIRT: 4-week physical therapy with 4 daily sessions (1 hour each), 5days/week, in a hospital setting. The first session comprises cardiovascular warm-up activities, relaxation, muscle stretching, exercises to improve the range of motion of different joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes exercises to improve balance and gait using stabilometric platform,treadmill plus, crossover and cycloergometer. The third and fourth pertain occupational and speech therapy.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Osteopathic Manipulative Treatment (SOMT)+ Multidisciplinary Intensive Rehabilitation Treatment (MIRT)
Description: SOMT: 4-week of sham osteopathic therapeutic program with a weekly session of osteopathic examination and manipulation in ambulatory setting.~MIRT: 4-week physical therapy with 4 daily sessions (1 hour each), 5days/week, in a hospital setting. The first session comprises cardiovascular warm-up activities, relaxation, muscle stretching, exercises to improve the range of motion of different joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes exercises to improve balance and gait using stabilometric platform,treadmill plus, crossover and cycloergometer. The third and fourth pertain occupational and speech therapy.
Study: NCT04870710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial electrical stimulation
Description: Electrical stimulation to the extrastriate visual cortex.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial electrical stimulation
Description: Electrical stimulation to the extrastriate visual cortex.
Study: NCT04815044

Intervention type: OTHER
Intervention: Pregnancy
Description: Experiences from being pregnant when having a history of eating disorder

Intervention type: OTHER
Intervention: Post-Partum
Description: Experiences from the post-partum period when having a history of eating disorder
Study: NCT00303199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZIO-101 (Darinaparsin)
Description: IV zio-101 (Darinaparsin) give for 5 consecutive days to be repeated every 28 days for up to 6 months
Study: NCT00881179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)
Study: NCT02130466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trametinib
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: oral tablet
Study: NCT01060202

Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Patients receiving bortezomib injection intravenously (into a vein) 1.3 mg/m2 twice a week for 21 days will be observed.
Study: NCT03082196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test varnish
Description: Topical application of test varnish to the teeth 4 times per year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard varnish
Description: Topical application of test varnish to the teeth 4 times per year
Study: NCT02068495

Intervention type: DRUG
Intervention: Candesartan cilexetil/Amlodipine besilate
Description: Candesartan cilexetil/Amlodipine besilate tablets
Study: NCT01502605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Aminolevulinic Acid
Description: A one time, single-dose administration of ALA is planned 4 hours pre-operatively the day of surgery. ALA will be mixed in the minimum volume of sterile water or juice immediately before use and given as a single oral bolus. Once ALA has been administered, patients will be kept in subdued lighting away from sunlight.
Study: NCT01732627

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine
Description: 0.5 milliliter (mL), Intramuscular (IM)
Study: NCT01245946

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Photodynamic therapy: 2 sessions separated by 2 weeks of TDF with topical ALA20% for 1.5 hrs, then irradiated with red light (Waldmann lamp) at a fluence of 37 J/cm2 for 7-9 minutes. From the sixth week will begin adapalene 0.1% gel until 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: Conventional therapy: Topical adapalene gel 0.1% at night for 12 weeks plus doxycycline 100 mg / day for 6 weeks.
Study: NCT03076268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treinta Millones de Palabras - Visitas al Hogar
Description: TMP-Visitas al Hogar is a cultural and linguistic adaptation of the TMW-Home Visiting curriculum into Spanish. The 12-module curriculum has been translated into Spanish and adapted to address concerns that are vital to mono- and bilingual Spanish-speaking families, including the broadening research base for when to introduce a second language to a child and the benefits of bilingualism.
Study: NCT00654901

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hep B-PRP~T vaccine (Batch 1)
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hep B-PRP~T vaccine (Batch 2)
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hep B-PRP~T vaccine (Batch 3)
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix Hexa™
Description: 0.5 mL, Intramuscular
Study: NCT00895700

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: web-based multifactorial intervention
Description: 12-week multi-factorial web-based behavioral intervention comprised of psycho-education, cognitive behavioral therapy (CBT) and relaxation therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web-based multifactorial intervention
Description: 12-week multi-factorial web-based behavioral intervention comprised of psycho-education, cognitive behavioral therapy (CBT) and relaxation therapy
Study: NCT01732627

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W 135 Combined
Description: 0.5 mL, Subcutaneous (SC)
Study: NCT01039558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ecabet sodium
Description: Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lansoprazole
Description: Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lansoprazole
Description: Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
Study: NCT00187135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 1. Fentanyl - 1 mcg/kg in 3 ml normal saline~2. Fentanyl - 0.5 mcg/kg in 3 ml normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 1. Fentanyl - 1 mcg/kg in 3 ml normal saline~2. Fentanyl - 0.5 mcg/kg in 3 ml normal saline
Study: NCT02130466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study: NCT01740700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: p-Branch®
Description: Instead of making a large incision in the abdomen, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
Study: NCT03960697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walk out from operating room
Description: After the surgery of laparoscopic total or partial nephrectomy， patients will be encouraged to walk out from the operating room and return to the ward by walking under the condition of stable physiological parameters, painlessness, clear consciousness and normal muscle strength of lower limb
Study: NCT01155752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmozyme single use ampule
Description: • Each Pulmozyme single use ampule delivers 2.5 mL (2.5 mg) of the sterile solution to the nebulizer bowl. The aqueous solution contains 1.0 mg/mL dornase alfa, 0.15 mg/mL calcium chloride dihydrate, and 8.77 mg/mL sodium chloride.
Study: NCT02893748

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HyGIeaCare Prep
Description: Patients will receive the HyGIeaCare Prep, which is an open colon lavage system using warm water by gravity drip to evacuate the colon by stimulating peristalsis to cleanse the colon prior to colonoscopy.
Study: NCT01155752

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identical placebo
Study: NCT00136786

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Memantine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Memantine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Memantine
Study: NCT02708225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: medical clown
Description: a medical clown will assist the child during the performance of pulmonary function test
Study: NCT03495388

Intervention type: DRUG
Intervention: Oxycodone
Description: Post-op pain management medication
Study: NCT04419844

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tar with Botox
Description: Evaluation of TAR technique in the treatment of huge abdominal wall hernia and large abdominal wall defect with Botox injection .

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tar with Botox
Description: Evaluation of TAR technique in the treatment of huge abdominal wall hernia and large abdominal wall defect with Botox injection .
Study: NCT03292848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Tablet
Study: NCT02228733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074
Description: Comparisons of different doses of study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KBP-5074
Description: Comparisons of different doses of study drug
Study: NCT04063293

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: PRP injection into tha anal canal in patients underwent low anterior resection for rectal cancer
Study: NCT03721120

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: InvisionFirst® molecular panel
Description: During the first visit, liquid biopsy will be performed using the InVisionFirst® panel. Cytological or histological sampling will be planned. According to InVisionFirst® results, treatment will be initiated:~* regardless of cytological/histological and tissue molecular analysis in case of EGFR, BRAF V600E-mutation, ALK- or ROS1-rearrangement identified on InvisionFirst® panel.~* regardless of molecular characterization performed on tissue sample in case of ERBB2-, BRAF non V600E-, c-MET-, KRAS-,LKB1-, NTRK and/or RET mutation on InVisionFirst® panel. Treatment will be based on pathology results and if appropriate on PD-L1 level of expression.~* for patients with none of the previous alterations, treatment will be initiated after obtaining pathology results and genomic characterization from the tumor tissue analysis.
Study: NCT04687943

Intervention type: COMBINATION_PRODUCT
Intervention: PELOID therapy, kinesio tape, exercise
Description: 126 patients diagnosed with lateral epicondylitis will be divided into 3 groups. Totally 15 sessions of peloid therapy for 42 patients in 1 group for 3 weeks, 5 days a week, 2 sessions of muscle and fascia correction techniques for 3 weeks in the second group for 3 weeks, and 3 sets per day for 42 patients in the third group for 3 weeks. You will be given 10 repetitive home workouts.

Intervention type: COMBINATION_PRODUCT
Intervention: PELOID therapy, kinesio tape, exercise
Description: 126 patients diagnosed with lateral epicondylitis will be divided into 3 groups. Totally 15 sessions of peloid therapy for 42 patients in 1 group for 3 weeks, 5 days a week, 2 sessions of muscle and fascia correction techniques for 3 weeks in the second group for 3 weeks, and 3 sets per day for 42 patients in the third group for 3 weeks. You will be given 10 repetitive home workouts.

Intervention type: COMBINATION_PRODUCT
Intervention: PELOID therapy, kinesio tape, exercise
Description: 126 patients diagnosed with lateral epicondylitis will be divided into 3 groups. Totally 15 sessions of peloid therapy for 42 patients in 1 group for 3 weeks, 5 days a week, 2 sessions of muscle and fascia correction techniques for 3 weeks in the second group for 3 weeks, and 3 sets per day for 42 patients in the third group for 3 weeks. You will be given 10 repetitive home workouts.
Study: NCT04178174

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR boost and de-escalated chemoradiation
Description: Stereotactic body radiotherapy boost to the gross tumor volume to a dose of 14 Gy in 2 fractions, followed by cisplatin-based chemoradiation to a dose of 40 Gy in 20 fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard chemoradiation
Description: Standard Cisplatin-based chemoradiation to a dose of 70 Gy in 33 fractions
Study: NCT04325022

Intervention type: DEVICE
Intervention: Primary Total Hip Arthroplasty
Description: Primary Total Hip Arthroplasty using the OR3O Dual Mobility System in combination with compatible components
Study: NCT03169803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroTronik CANS Therapy™ System
Description: The NeuroTronik CANS Therapy™ System is a percutaneous, catheter-based, bedside electrical stimulation system. The System consists of the single-use, disposable NeuroCatheter™ and NeuroCatheter™ Placement Kit, along with the reusable, bedside NeuroModulator™ Development System, and the NeuroTronik CANS Therapy™ Cable.
Study: NCT01455935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-platelets and statin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alteplase
Description: Full dose Intravenous thrombolysis~* 0.9 mg/kg~* Maximum dose is 90 mg~* 10% of the dose will be given over one minute~* 90% of the dose will be infused over 1 hour~* Admission to Neuro Intensive Care Unit(NICU) for 24 hours if no complications~* Neuro checks every 5 minutes during the infusion~* Neuro checks every hour after the infusion for 24 hours

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intra arterial intervention
Description: 1. Intra arterial Activase (Maximum dose of 22 mg)~2. MERCI device (Maximum of 3 tries per device, no standard time frame for how long the procedure takes)~3. PENUMBRA device (no standard time frame for how long the procedure takes)
Study: NCT03020225

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: White cheese
Description: animal protein food source: White cheese (contains 30g protein), intact, plus 250ml mineral water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green peas
Description: Green peas (contains 30g protein), intact, cooked, plus 250ml mineral water

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mankai
Description: Wolffia globosa (Mankai, contains 30g protein), intact, cooked, plus 250ml mineral water
Study: NCT01412801

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B streptococcus vaccine
Description: Subjects receive one dose of 5 μg of each of the 3 glycoconjugates present in the Group B streptococcus vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B streptococcus vaccine
Description: Subjects receive one dose of 5 μg of each of the 3 glycoconjugates present in the Group B streptococcus vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B streptococcus vaccine
Description: Subjects receive one dose of 5 μg of each of the 3 glycoconjugates present in the Group B streptococcus vaccine.
Study: NCT02415179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Mometasone/formoterol
Description: Inhaled Mometasone/formoterol (100/5 microgram) 2 puffs twice daily via metered dose inhaler for 6 weeks
Study: NCT02893748

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Screening colonoscopy as per standard of care.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy
Description: Screening colonoscopy as per standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: polyethylene glycol (PEG)
Description: PEG preparation to be delivered in two doses - 1/2 the night before and 1/2 the morning of the colonoscopy
Study: NCT02415179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled Fluticasone/Salmeterol
Description: Inhaled Fluticasone/Salmeterol (125/25 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
Study: NCT04860947

Intervention type: DIAGNOSTIC_TEST
Intervention: Brain MRI
Description: * Axial DWI with ADC card~* Axial 2D TSE T2/DP or 3DT2~* Gadolinium injection (0.1 mmol/kg)~* 3D Fluid-attenuated inversion recovery~* 3D T1 with Gadolinium injection.
Study: NCT02676154

Intervention type: DRUG
Group type: OTHER
Intervention: Fesoterodine
Description: 4mg, oral, once daily for 12 weeks; dose adjustments may be permitted.
Study: NCT01555619

Intervention type: DEVICE
Intervention: CRT-D System
Description: Implantation of a CRT-D System